Bempikibart (ADX-914) is under development for the treatment of atopic dermatitis and alopecia areata. It is administered through subcutaneous route and acts by targeting interleukin-7 receptor (IL-7R ...
SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 ...
WALTHAM, Mass. - Q32 Bio Inc. (NASDAQ: QTTB), a biotechnology firm specializing in immune system therapeutics, has announced plans to progress its drug candidate bempikibart after observing ...
SIGNAL-AA demonstrated encouraging clinical activity of bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 ...
WALTHAM, Mass. - Q32 Bio Inc. (NASDAQ: QTTB), a biotechnology firm specializing in immune system therapeutics, has announced plans to progress its drug candidate bempikibart after observing promising ...
SIGNAL-AD is a Phase 2a clinical trial evaluating lead drug candidate Bempikibart in adult patients with persistent, moderate-to-severe atopic dermatitis, comprising of two parts - Part A and Part B.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback